Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has shared an update.
CSL Limited announced the issuance of 150,485 ordinary fully paid securities under an employee incentive scheme, which are set to be quoted on the Australian Securities Exchange. This move is part of CSL’s efforts to incentivize its workforce and align employee interests with company performance, potentially impacting its market positioning and stakeholder engagement positively.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its work in plasma-derived therapies and influenza vaccines, catering to a global market.
Average Trading Volume: 1,021,659
Technical Sentiment Signal: Sell
Current Market Cap: A$101.5B
For an in-depth examination of CSL stock, go to TipRanks’ Overview page.